Tylenol Pregnancy Warning Sparks Controversy Amid Autism Claims

WASHINGTON, D.C. — An old social media post from Tylenol warning against using its products during pregnancy has resurfaced. This comes just two days after the Trump administration suggested a link between Tylenol use during pregnancy and an increased risk of autism. The post, originally from 2017, was highlighted by the U.S. Department of Health and Human Services on Wednesday with the caption: ‘No caption needed.’

The reemergence of the post has led to growing concern and confusion, especially after President Donald Trump stated during a press conference that the use of Tylenol could be associated with a significantly heightened risk of autism. A representative from Kenvue, Tylenol’s parent company, responded by saying that the tweet was ‘incomplete’ and failed to convey the full safety guidance for Tylenol, which remains unchanged.

Kenvue emphasized that its products are safe when used according to the label and advised consumers to consult their healthcare provider regarding the use of any over-the-counter medications. ‘Our products are effective and safe when used as directed on the product label,’ the spokesperson stated.

This week, Kenvue also released a statement refuting claims linking acetaminophen, the active ingredient in Tylenol, to autism. The company argued that abstaining from medications like acetaminophen could pose risks to both mothers and their unborn children. Trump’s announcement was part of a broader initiative to reevaluate FDA guidance on acetaminophen, suggesting that the evidence linking it to autism would be investigated further, raising alarm among healthcare professionals and consumers alike.

The resurfacing of the 2017 post has acted as a catalyst for discussions surrounding the relationship between medication use during pregnancy and autism, with experts urging for more thorough investigation and communication with expectant mothers.